Taiga_Logo_vF.png

Taiga Biotechnologies, Inc. is developing a new class of cell-based therapies utilizing autologous immune cells and allogeneic stem cells. 

TAIGA HIGHLIGHTS

overall_edited.jpg

New class of cellular therapy, with an agnostic approach.

Platform technology with “Plug-and-Play” features.

Product manufacturing time - less than 24 hours.

Access to global markets with active clinical trials.

Opportunities for additional platforms & products.

OUR VISION: SOLID TUMORS & INFECTIOUS DISEASE

difference.001.jpeg